DE69822626T8 - Verwendung eines nitroxids oder seiner prodrugs zur prophylaktischen und therapeutischen behandlung von krebs - Google Patents

Verwendung eines nitroxids oder seiner prodrugs zur prophylaktischen und therapeutischen behandlung von krebs Download PDF

Info

Publication number
DE69822626T8
DE69822626T8 DE69822626T DE69822626T DE69822626T8 DE 69822626 T8 DE69822626 T8 DE 69822626T8 DE 69822626 T DE69822626 T DE 69822626T DE 69822626 T DE69822626 T DE 69822626T DE 69822626 T8 DE69822626 T8 DE 69822626T8
Authority
DE
Germany
Prior art keywords
cancer
nitroxide
prodrug
prophylactic
therapeutic treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
DE69822626T
Other languages
English (en)
Other versions
DE69822626D1 (de
DE69822626T2 (de
Inventor
B. James MITCHELL
Angelo Russo
Marie Anne DELUCA
Krishna Murali CHERUKURI
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
US Government
Original Assignee
US Department of Health and Human Services
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by US Department of Health and Human Services filed Critical US Department of Health and Human Services
Publication of DE69822626D1 publication Critical patent/DE69822626D1/de
Publication of DE69822626T2 publication Critical patent/DE69822626T2/de
Application granted granted Critical
Publication of DE69822626T8 publication Critical patent/DE69822626T8/de
Active legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
DE69822626T 1997-05-27 1998-05-27 Verwendung eines nitroxids oder seiner prodrugs zur prophylaktischen und therapeutischen behandlung von krebs Active DE69822626T8 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US4772497P 1997-05-27 1997-05-27
US47724P 1997-05-27
PCT/US1998/010685 WO1998053835A1 (en) 1997-05-27 1998-05-27 The use of a nitroxide or a prodrug thereof in the prophylactic and therapeutic treatment of cancer

Publications (3)

Publication Number Publication Date
DE69822626D1 DE69822626D1 (de) 2004-04-29
DE69822626T2 DE69822626T2 (de) 2004-08-12
DE69822626T8 true DE69822626T8 (de) 2005-02-03

Family

ID=21950574

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69822626T Active DE69822626T8 (de) 1997-05-27 1998-05-27 Verwendung eines nitroxids oder seiner prodrugs zur prophylaktischen und therapeutischen behandlung von krebs

Country Status (10)

Country Link
EP (1) EP0986393B1 (de)
JP (3) JP4856294B2 (de)
AT (1) ATE262330T1 (de)
AU (1) AU746505B2 (de)
CA (1) CA2289017C (de)
DE (1) DE69822626T8 (de)
DK (1) DK0986393T3 (de)
ES (1) ES2216286T3 (de)
PT (1) PT986393E (de)
WO (1) WO1998053835A1 (de)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6096759A (en) * 1997-09-19 2000-08-01 Georgetown University Method for treating essential hypertension
CA2335986A1 (en) * 1998-06-26 2000-01-06 Simeng Suy Use of tempo and tempo derivatives for inducing cell death
US20040219201A1 (en) * 2001-12-06 2004-11-04 Yechezkel Barenholz Tempamine compositions and methods of use
CA2527522A1 (en) * 2003-05-29 2004-12-09 Kenneth Chang Methods of using nitroxides in conjunction with photosensitizers and sonosensitizers
US20120046314A1 (en) * 2005-02-02 2012-02-23 Mitos, Inc. Nitroxides for use in treating or preventing neoplastic disease
US8466130B2 (en) 2009-09-04 2013-06-18 Colby Pharmaceutical Company Mitochondria targeted cationic anti-oxidant compounds for prevention, therapy or treatment of hyper-proliferative disease, neoplasias and cancers
EP2139522A2 (de) * 2007-03-06 2010-01-06 Colby Pharmaceutical Company Auf mitochondrien gerichtete kationische antioxidationsverbindungen zur prävention, therapie oder behandlung von hyperproliferativen erkrankungen, neoplasien und karzinomen
WO2011066537A1 (en) 2009-11-30 2011-06-03 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Nitroxide therapy for the treatment of von hippel - lindau disease (vhl) and renal clear cell carcinoma (rcc)
US10231959B2 (en) 2016-03-23 2019-03-19 Louis Habash Increasing expression level of apoptosis-related genes by treating a human subject with a nitroxide
JP2019509352A (ja) * 2016-03-23 2019-04-04 ルイス ハバシュ， ヒトの被験物質をニトロキシドで処理することによってａｐｏｐｔｏｓｉｓ関連遺伝子の発現レベルを増加させる
US20180078539A1 (en) 2016-03-23 2018-03-22 Louis Habash T-cell regulation in t-cell mediated diseases by reducing pathogenic function of th17 in a human subject through treatment with a nitroxide

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4758580A (en) * 1985-06-26 1988-07-19 Yamanouchi Pharmaceutical Co., Ltd. Inhibiting growth of tumors with certain substituted phenoxy dimethyl alkanoic acids, esters or salts
ATE113469T1 (de) * 1990-06-21 1994-11-15 Edith Dr Huland Verwendung zytokinhaltiger aerosole und zytokinhaltige aerosole selbst.
US6605619B1 (en) * 1992-03-20 2003-08-12 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Nitroxides as protectors against oxidatives stress
EP0809511A1 (de) * 1995-02-16 1997-12-03 F. Hoffmann-La Roche Ag Hemmung der angiogenese mittels interleukin-12

Also Published As

Publication number Publication date
PT986393E (pt) 2004-06-30
JP2009185034A (ja) 2009-08-20
WO1998053835A1 (en) 1998-12-03
JP2002500671A (ja) 2002-01-08
AU746505B2 (en) 2002-05-02
DE69822626D1 (de) 2004-04-29
DE69822626T2 (de) 2004-08-12
EP0986393B1 (de) 2004-03-24
ATE262330T1 (de) 2004-04-15
CA2289017A1 (en) 1998-12-03
CA2289017C (en) 2008-07-22
EP0986393A1 (de) 2000-03-22
JP5270413B2 (ja) 2013-08-21
DK0986393T3 (da) 2004-07-05
AU7598798A (en) 1998-12-30
JP4856294B2 (ja) 2012-01-18
ES2216286T3 (es) 2004-10-16
JP2013121964A (ja) 2013-06-20

Similar Documents

Publication Publication Date Title
DE69634776D1 (de) Verwendung eines r-nsaid als chemoschützendes mittel zur behandlung kolorektales krebs
ATE271385T1 (de) Verwendung von cyclooxygenase-2 inhibitoren zur behandlung und verbeugung von neoplasia
DE69433889D1 (de) Anwendung von 1,2,4-benzotriazinoxiden zur Herstellung eines Arzneimittels zur Behandlung von Tumoren
ATE499934T1 (de) Verwendung von (3.2.0) heterocyclischen verbindungen und ihren analoga zur behandlung von krebs
ATE198044T1 (de) Hydroperoxeicosatetraensäure derivate enthaltende zusammensetzungen und verfahren zur verwendung zur behandlung des trockenen auges
ATE396174T1 (de) Hydroxyalkylaminderivate als beta-secretase- inhibitoren und deren verwendung zur behandlung der alzheimerschen krankheit oder ähnlicher krankheiten
DE60124085D1 (de) Pde-v hemmer zur behandlung von morbus parkinson
DE60316779D1 (de) Thiadiazolylpiperazinderivate geeignet für die behandlung bzw. prävention von schmerzen
ATE242632T1 (de) Verwendung von betulinsäure-derivaten zur behandlung und vorbeugung von melanomen
ATE399782T1 (de) Zur behandlung von schmerzen geeignete phenylcarbonsäureamidverbindungen
ATE170077T1 (de) Verfahren zur behandlung von krebs durch kombinationstherapie mit 2'- halomethylidenderivaten und einem s- oder m-phase spezifischen antineoplastischen wirkstoff
ATE412646T1 (de) Zur behandlung von schmerzen geeignete therapeutische mittel
DE69822626D1 (de) Verwendung eines nitroxids oder seiner prodrugs zur prophylaktischen und therapeutischen behandlung von krebs
ATE260282T1 (de) Aromatische ester von camptothecinen und verfahren zur behandlung von krebserkrankungen
DE69125216D1 (de) Aminoalkanesulfonsäurederivate und pharmazeutische Zusammensetzungen davon zur Prävention oder Behandlung von Herzerkrankungen
DE69707372D1 (de) Verwendung eines Phosphorsäurediesters zur Herstellung eines Arzneimittels zur Behandlung von Akne
ATE180669T1 (de) Verwendung von pregnanderivaten zur behandlung von tumoren
ATE281841T1 (de) Verfahren zur herstellung von mikania extrakten enthaltend mikanolide und dihydromikanolide und verwendung in der behandlung proliferativer erkrankungen
ATE217191T1 (de) Verwendung von phanquinon zur behandlung von alzheimer's krankheit
ATE369856T1 (de) Verfahren zur behandlung von glaukom
ATE315387T1 (de) Verwendung von substituierten 6- dimethylaminomethyl-1-phenyl- cyclohexanverbindungen zur therapie der harninkontinenz
DE50109320D1 (de) Verwendung von 6-dimethylaminomethyl-1-phenyl-cyclohexanverbindungen zur therapie der harninkontinenz
DE69633673D1 (de) Verwendung von Halofuginon zur Herstellung eines Medikaments zur Vorbeugung von Neovaskularisation und zur Behandlung bösartiger Tumore
DE60219680D1 (de) Amin-1,2- und -1,3-diolverbindungen und deren verwendung zur behandlung von alzheimer-krankheit
ATE350034T1 (de) Verwendung von epothilone zur behandlung hyperparathyreoidismus

Legal Events

Date Code Title Description
8327 Change in the person/name/address of the patent owner

Owner name: THE GOVERNMENT OF THE UNITED STATES OF AMERICA AS

8364 No opposition during term of opposition